Promedior, a clinical-stage biotechnology company, is developing immunotherapies to treat fibrosis. The company’s lead product candidate is PRM-151, a recombinant form of human pentraxin-2 formulated for intravenous injection.
Promedior is a clinical-stage biotechnology company pioneering the development of targeted therapeutics to treat diseases involving fibrosis.
Promedior's proprietary platform is based upon Pentraxin-2, an endogenous human protein that is a monocyte/macrophage differentiation factor specifically active at the site of tissue damage and works as an agonist with the potential to both prevent and reverse fibrosis. The lead product candidate is a recombinant form of human Pentraxin-2 called PRM-151.
By acting as a master regulator upstream in the fibrosis cascade, Pentraxin-2 therapeutics harness the healing power of the innate immune system and open up new opportunities to treat a wide range of systemic fibrotic diseases for which there are no approved therapies. PRM-151 has been shown to be generally safe and well-tolerated in healthy volunteers and in idiopathic pulmonary fibrosis (IPF) patients, with some encouraging exploratory efficacy signals seen in IPF. Clinical development is continuing in IPF as well as in myelofibrosis, currently in a Phase 2 study.
From the publishers of Nature, the BioPharma Dealmakers website brings together life sciences companies and individuals looking to identify and attract partners and dealmaking opportunities. It provides insights into dealmaking trends from BioPharma Dealmakers Editors, profiles from companies looking to partner, tools for networking and sharing knowledge, and the opportunity for sponsoring companies to showcase their expertise. BioPharma Dealmakers is THE destination for partnering professionals looking to make connections and get the latest on their industry.